0HA3 Stock Overview
A clinical-stage company, develops gene therapy product candidates to treat ocular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Adverum Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.76 |
| 52 Week High | US$29.50 |
| 52 Week Low | US$4.61 |
| Beta | 0.90 |
| 1 Month Change | -21.30% |
| 3 Month Change | -32.70% |
| 1 Year Change | -39.75% |
| 3 Year Change | -74.27% |
| 5 Year Change | n/a |
| Change since IPO | -93.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HA3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -13.5% | -5.1% | -2.2% |
| 1Y | -39.7% | -24.5% | 2.4% |
Return vs Industry: 0HA3 underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0HA3 underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| 0HA3 volatility | |
|---|---|
| 0HA3 Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HA3's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HA3's weekly volatility has decreased from 13% to 8% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 121 | Laurent Fischer | adverum.com |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. Fundamentals Summary
| 0HA3 fundamental statistics | |
|---|---|
| Market cap | US$98.60m |
| Earnings (TTM) | -US$94.11m |
| Revenue (TTM) | US$1.00m |
98.6x
P/S Ratio-1.0x
P/E RatioIs 0HA3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HA3 income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$68.22m |
| Gross Profit | -US$67.22m |
| Other Expenses | US$26.89m |
| Earnings | -US$94.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.52 |
| Gross Margin | -6,722.40% |
| Net Profit Margin | -9,411.10% |
| Debt/Equity Ratio | 0% |
How did 0HA3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adverum Biotechnologies, Inc. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Daniil Gataulin | Chardan Capital Markets, LLC |